Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Medication and Behavioral Treatment in Young Children With Comorbid ASD and ADHD
NCT03242772Phase 2Terminated
- Sponsor
- Duke University
- Start
- Dec 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing ESDM + Amphetamine with ESDM + Placebo (2 arms). Primary endpoint: Change in Amount and Quality of Joint Engagement Between the Child and Parent During a Semi-structured 6 Minute Parent Child Interaction Task at 11 weeks. Started Dec 2018; status: terminated.
02
Drugs
amphetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03242772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03242772.